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Abstract
This chapter aims to identify, among the dopaminergic and noradrenergic molecules
strongly associated to aetiopathogenesis of the disorder, potential genetic and bio‐
chemical markers linked to ADHD diagnosis and to assess whether treatments can
change peripheral levels of a biomarker, to be then useful, if tested, as a response pre‐
dictor.
The results, based on literature research, evidenced a role of some molecules such as
SLC6A3, DRD4, MHPG, MAOA, NE, SLC6A2, DBH, COMT that could represent, in
this order, a hypothetical signature of genetic and biochemical markers useful for
ADHD diagnosis. From this hypothetical signature, the NE metabolite MHPG result‐
ed, after a meta-analytic approach, the main molecule whose urinary levels were in‐
fluenced by the d-AMP treatment. Urinary MHPG levels were decreased after
stimulants administration only in the responder patients, indicating that MHPG could
be a useful predictor of the response to these drugs. This, along with the well-report‐
ed correlation between decrease in MHPG and behavioral improvements after d-AMP
treatment, focuses attention on MHPG as a potential mediator of stimulant drug re‐
sponse, in addition to a potential useful biological marker for diagnostic assessment.
Future studies on specificity, sensitivity and replication of these findings are needed.
Keywords: dopaminergic systems, noradrenergic systems, biomarkers, ADHD, diag‐
nosis, treatment
1. Introduction
The attention-deficit-hyperactivity disorder (ADHD) is one of the most frequently diagnosed
psychiatric disorders in children with an estimated worldwide-pooled prevalence of about
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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5.3–8.7% [1–3], persisting through adolescence and adulthood with a prevalence of up to 5%
[4, 5]. The core symptoms include increased inattention and/or hyperactivity and impulsivity
as well as lack of emotional self-control and motivation.
ADHD is a complex and heterogeneous disorder and its aetiology is not yet completely
understood [6]. Despite evidence that environmental factors (i.e. maternal smoking, low
birthweight, prematurity) play a significant role in its aetiology, classical genetics studies
support a strong genetic contribution for ADHD. The risk of ADHD among parents of children
with ADHD is increased by twofold to eightfold compared with the population rate [7]. A
meta-analysis of 20 pooled twin studies estimated an average hereditability of 76%, suggesting
that ADHD is one of the disorders with the strongest genetic component in psychiatry [7].
Despite these high heritability estimates, identification of genes that confer susceptibility to
ADHD has been a slow and difficult process and current findings from both candidate gene
studies and genome-wide association studies (GWAS) suggest that ADHD is a polygenic
disorder with minor contribution from each individual susceptibility gene [for reviews, see 8,
9]. In particular, it seems likely that the high heritability of ADHD is determined by common
variants as well as by rare deletions or duplications known as copy number variants (CNVs)
[10]. A useful database on the genomic studies in ADHD is to date available (http://
adhd.psych.ac.cn/index.do).
Multiple neural pathways have been implicated in the development of ADHD and the most
studied is the dopaminergic neurotransmission based on the observed dopamine (DA)
deficiency in children with ADHD and on the therapeutic benefits provided by methylpheni‐
date (MPH), a DA agonist. A meta-analysis of commonly studied candidate genes has revealed
associations between ADHD and variants of the dopamine transporter (DAT1) gene (SLC6A3)
and the dopamine D4 and D5 receptor genes (DRD4, DRD5) [11]. Moreover, significant
peripheral alterations in norepinephrine (NE) levels and its main metabolites have been
observed in ADHD patients [12]. This along with pharmacological evidence support that the
noradrenergic system also plays a significant role in the aetiopathogenetic mechanisms of this
illness.
1.1. Diagnosis
The clinical characterizations, underlying concepts, and nomenclature of the dysfunctions
have changed over the time and hyperactive, inattentive, and impulsive children have been
described by several authors during the past 200 years. First clinical description of attentional
disorders was reported by the German physician, Melchior Adam Weikard, in 1775, and the
successive mentioning of ADHD was described in 1902 by the British pediatrician, Sir George
Still. In 1952, the APA issued the first DSM but only the second edition included “hyperkinetic
impulse disorder”. This name was further changed in attention deficit disorder (ADD) with/
without hyperactivity in 1980 (DSM-III). The APA released a revised version of the DSM-III
in 1987 where they changed the name definitively to attention-deficit-hyperactivity disorder
(ADHD). The three subtypes (combined type ADHD, predominantly inattentive type ADHD,
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predominantly hyperactive-impulsive type ADHD) were established in 2000 (DSM-IV) (for
review, see [13]). Recently, NIMH approved the Research Domain Criteria (RDoC) project
where a set of assumptions permit to find a new classification system, by integrating genetics,
imaging and cognitive information [14]. The RDoC suggests that a biomarker approach to
diagnosis may be a more valid way to classify complex mental disorders such as ADHD.
Biomarkers offer the opportunity to standardize and improve diagnostic assessment while
providing insights into aetiological mechanisms. To date, although biomarkers are success‐
fully used in predicting diseases such as cancer, there is no laboratory test that is used clinically
for the diagnosis of ADHD.
1.2. Treatment
Pharmacotherapy has an essential role in the treatment of ADHD [15].
Stimulants, such as MPH and dextro-amphetamine (d-AMP), are the most widely used
medications approved by the Unites States Food and Drug Administration (US-FDA) for the
treatment of ADHD in children [16], and more than 70% of children with ADHD respond to
these drugs [17]. These medications improve both the cognitive (inattention and impulsivity)
and the non-cognitive (hyperactivity) domains of the disorder [18]. They have virtually
identical clinical effects, although AMP formulations are modestly more efficacious than MPH
[19]. Usually, a child who responds to one stimulant drug also responds to the other, presum‐
ably because of the similar effect of the drugs on brain monoamine metabolism, and it is
generally assumed that the mechanism of at least some effects of these drugs involves DA. In
fact, preclinical studies have shown that both stimulants block the re-uptake of DA and NE
into the pre-synaptic neuron, and increase the release of these monoamines into the extra‐
neuronal space.
Other drugs used are the monoamine oxidase inhibitors (MAOIs) that block the breakdown
of serotonin (5-HT), NE, DA and increase the availability of these monoamines.
Proven alternate choices to stimulant medications include atomoxetine, guanfacine and
bupropion. Atomoxetine is a non-stimulant approved by the FDA for the treatment of ADHD.
It is in the class of medications known as selective NE re-uptake inhibitors. There is good level
of evidence provided by meta-analysis of efficacy for this drug [20–22]. Long-acting guanfacine
is in the group of medications known as alpha agonists. These medications were developed
for the treatment of high blood pressure but have also been used to treat children with ADHD
who have tics, sleep problems and/or aggression. It has recently been approved by the FDA
for the treatment of children with ADHD. Finally, bupropion is a unique type of antidepressant
that has been less frequently studied as a treatment for ADHD. Like stimulants and atomox‐
etine, it inhibits the re-uptake of both DA and NE but does not carry the potential risk of abuse
and dependence seen with stimulants.
Other alternative treatments, in addition to the behavioural therapy, regard the use of
pycnogenol, a herbal dietary supplement derived from French maritime pine bark extract [23]
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or pemoline, a central nervous system (CNS) stimulant, structurally different from AMP and
MPH, that acts via enhancing central dopaminergic transmission [24].
Although there are several treatments for ADHD, the mechanisms of action of these agents
are still unknown and to date no biological predictors of treatment response are available that
can be used in treatment planning.
1.3. Definition of a biomarker
The identification of genetic and biochemical markers might facilitate the differential diagnosis
of ADHD as well as allow better monitoring of treatment response or prediction of disorder
progression, and help to determine treatment strategy and the development of individualized
therapies.
According to US-FDA, a biomarker is defined as a characteristic that can be objectively
measured and evaluated as an indicator of a normal biological process, a pathogenic process
or a response to a therapeutic intervention [25, 26].
In other words, the identification of genetic and peripheral biomarkers, which provide
molecular signatures of disease, could potentially improve diagnostic classification. Also, the
identification and validation of biomarkers for a disorder have the potential application as
indicators of disease status, course of the illness and potentially as targets to monitor and
predict response to therapeutics.
A desirable diagnostic biomarker should meet several characteristics. In particular, (a) high
specificity and sensitivity (80 % for both); (b) reliability, reproducibility, inexpensiveness and
easy use; (c) independent confirmations by qualified researchers published in peer-reviewed
journals; (d) biomarker interpretation should allow comparison with other neurological
observations; (e) information provided by a biomarker should be timely and cost-effective with
significant clinical usefulness; (f) technology for a test should be available and tolerated by the
general target population; (g) methodology should be cheap, simple and easily integrated into
a clinical care practice [27].
To date, it is well accepted that a single biomarker is very unlikely to provide enough infor‐
mation to identify cellular and metabolic pathways involved in a particular individual. Thus
the identification of a signature set of biomarkers for a disorder each based on their underlying
biological pathways will be the most effective for diagnosis and treatment selection [28].
Biological samples useful for a diagnostic test should be ideally non-invasive, which is
especially important in psychiatric disorders, since patients often have conditions that should
typically not be exacerbated by additional stress. Some studies utilize fluids such as brain tissue
or cerebrospinal fluid (CSF), which represent an invasive procedure, whereas urine and saliva
are the best non-invasive procedures.
On this basis, the main aims of this chapter are: (a) to identify, among the dopaminergic and
noradrenergic molecules strongly associated to aetiopathogenesis of the disorder, potential
genetic and biochemical markers linked to ADHD diagnosis; (b) to assess whether treatments
can change peripheral levels of a biomarker, to be then useful, if tested, as a response predictor.
ADHD - New Directions in Diagnosis and Treatment58
2. Role of dopaminergic and noradrenergic systems as potential genetic and
biochemical markers in ADHD diagnosis
In this paragraph, we report evidence on the involvement of the most relevant components of
dopaminergic and noradrenergic pathways with ADHD aetiopathogenesis as well as with
neuropsychological, neuroimaging, treatment response, biochemical and gene expression
features. This is to identify, among these molecules, the best potential markers linked to ADHD
diagnosis and thus to characterize a putative signature set of genetic and biochemical markers
for ADHD. Here, we report positive associations of polymorphisms (single-nucleotide
polymorphisms – SNPs and variable number of tandem repeats – VNTR) in different genes
(genomics) or alterations in peripheral levels of different proteins (metabolomics) with ADHD.
2.1. Method
The literature research was conducted by using two online electronic databases (PubMed
http://www.ncbi.nlm.nih.gov/pubmed/, database ADHD http://adhd.psych.ac.cn/index.do)
from inception until December 2014, for all available studies on genomics, metabolomics
neuropsychological, neuroimaging, dopamine, norepinephrine, metabolites, metabolism
enzymes, levels, biochemical, expression, response and “ADHD” or “Attention Deficit
Hyperactivity Disorder”. Once articles had been collected, bibliographies were manually
searched for additional eligible studies. The literature search was performed by two individ‐
uals independently.
2.2. Results
2.2.1. Dopamine neurotransmitter system
The DA hypothesis for ADHD’s neurological mechanism is the most probable and studied
theory. It is based on a malfunctioning or decreased functioning of the DA system in particular
regions of the brain, supported by data derived from pharmacological and neuroimaging
studies, from animal models as well as for its involvement in the regulation of functions such
as attention or psychomotor activity, which are impaired in ADHD [29].
2.2.1.1. Dopamine Transporter Gene (DAT1, SLC6A3)
The main function played by DAT1 is to regulate DA availability. In particular, it removes DA
from the synaptic cleft into the pre-synaptic neuron or releases DA into the extracellular space.
Its involvement in the aetiopathogenetic mechanisms of ADHD is supported by the evidence
that dopaminergic neurotransmission is controlled by the DAT1 protein, DAT1 is the main
target for MPH and AMP, knockout mice for DAT1 present hyperactivity and deficits in
inhibitory behaviour, DAT1 has been mapped near to 5p13, a susceptibility locus for ADHD.
The most studied DAT1 variant is a VNTR of 40 base pairs located at the 3′-untranslated region
(3′-UTR) of the gene. The ten repeat (10R) and nine repeat (9R) alleles are the most common.
A recent meta-analysis that pooled 34 studies on this polymorphism demonstrated an
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association between the 10R allele and ADHD susceptibility [11]. A single successive study
replicated this association, with the 10R allele conferring greater risk for ADHD symptoms
[30]. This allele has a functional effect because it correlates with increased DA concentrations
in CSF [31] and with higher DAT density in ADHD children in basal ganglia, a brain area
participating in inhibitory behaviours [32].
As reported in [33, 34], 10R allele was linked to specific neuropsychological and neuroimaging
functions and treatment response. In particular, this allele was associated to (a) sustained
attention, (b) executive functions, (c) response inhibition, (d) spatial attentional bias, (e)
abnormal reward-related ventral striatum activity, (f) diverse patterns of EEG responses, (g)
lower IQ, (h) reduced caudate volume, (i) abnormalities in vigilance and EEG activity in
response to MPH, (l) higher regional cerebral blood flow and poorer treatment response (Table
1).
2.2.1.2. Dopamine D4 Receptor (DRD4) gene
The DRD4 is a G-protein-coupled receptor belonging to the DA D2-like receptor family, which
acts to inhibit adenyl cyclase. It is involved in ADHD aetiopathogenetic mechanisms because
of its high expression in brain regions implicated in attention and inhibition such as anterior
cingulate cortex. Moreover, DRD4 was the first to be associated with personality trait common
in ADHD (novelty-seeking).
A highly polymorphic functional VNTR in the third exon has been frequently studied in
association studies. It comprises 11 copies of a 48-bp repeat sequence, where 4, 7 and 2R repeat
alleles are the most prevalent. Two meta-analyses confirmed that the 7R allele was associated
with ADHD susceptibility [11, 35]. Recently, rare variants and non-synonymous mutations in
the VNTR region of 7R allele have been identified in ADHD subjects [36], suggesting an allelic
heterogeneity in the VNTR as an important factor in the pathophysiology of ADHD.
As summarized in [33], this allele was associated to (a) cognitive markers such as speed of
processing, set shifting, and cognitive impulsiveness, (b) thinner pre-frontal and parietal
cortex, (c) enhanced response to MPH. Moreover, mRNA expression levels of DRD4 were
lower in ADHD [37] (Table 1).
2.2.1.3. Dopamine D5 Receptor (DRD5) Gene
The DRD5 is a G-protein-coupled receptor that belongs to the D1 class of DA receptors and
serves to stimulate adenyl cyclase activity. Some studies support its involvement in ADHD
aetiopathogenesis: (a) the expression of this gene is higher in hippocampus, a brain area
involved in ADHD pathogenesis; (b) DRD5 is implicated in synaptic strength in hippocampal
memory formation. The association between ADHD and a highly polymorphic dinucleotide
repeat of DRD5 ((CA)n), at the 5′ flanking region, has been the most studied. This variant
comprises 12 alleles and the 148-bp and 136-bp alleles are the most common. The 148-bp allele
is a risk factor for ADHD according to two meta-analyses [11, 35]. Moreover, it was found
associated to some neuropsychological features such as commission errors, omission errors
and reaction time variability [33] (Table 1).
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Genomics 
Dopaminergic 
system 
Dopamine transporter DAT1 
(SLC6A3) 
Encodes a transmembrane transport protein mediating the active reuptake of DA from the 
synapse and serves as a critical regulator of dopaminergic neurotransmission in the brain. 
3'-UTR 
VNTR 
10R 
higher expression levels 
Yes Yes Yes  Yes      
Dopamine D4 receptor (DRD4) 
A member of the dopamine D2-like receptor family inhibiting adenylcyclase. Expressed in 
frontal lobe regions (orbitofrontal cortex and anterior cingulated regions). 
Exon III 
VNTR 
7R 
less responsive 
Yes Yes  Yes Yes      
Dopamine D5 receptor (DRD5) 
A member of the dopamine D1-like receptors family. Expressed in amygdala, frontal cortex, 
hippocampus, striatum, basal forebrain, hypothalamus, cerebellum and thalamus. 
5′ Flank 
dinucleotide repeat 
148 bp 
Yes          
Metabolomics 
Dopamine 
(DA) 
In ADHD, the turnover is reduced with excessive re-uptake and intra-synaptic monoamine 
concentrations are decreased. 
      No  No No No 
Dihydroxy 
phenylacetic acid (DOPAC) 
Main DA metabolite.       No  No No 
No 
(BC) 
Homovanillic acid (HVA) Main DA metabolite.       No  No No Yes 
Genomics 
Noradrenergic 
system 
Norepinephrine transporter 
protein 1 
NET1 
(SLC6A2) 
Codes for a protein responsible for the re-uptake of NE from the synaptic cleft back into the 
pre-synaptic neuron. Expressed in the frontal lobes. It is actively involved in both 
noradrenergic and dopaminergic re-uptake and regulation in this region. 
Exon 9 
rs5569 
no risk allele 
    Yes      
Other polymorphisms Yes    Yes      
Metabolomics 
Norepinephrine 
(NE) 
It is released by noradrenergic neurons located in the specific central nervous system neurons.       Yes 
Yes 
after PYC 
No No No 
3-Methoxy-4-hydroxyphenyl 
Glycol (MHPG) 
Main metabolite of NE.       Yes 
Yes 
after d-AMP 
No 
Yes 
(yes RES) 
Yes 
Normetanephrine 
(NM) 
Main metabolite of NE.       No (BC)  No No Yes 
Vanillylmandelic acid 
(VMA) 
Other metabolite of NE.       Yes/No  No No(BC) Yes 
Neuropeptide Y 
(NPY) 
Co-localizes with catecholamine systems.    Yes   Yes     
Trace 
Amines 
Phenylethylamine 
(PEA) 
A DA receptor agonist, synthesized by the decarboxylation of phenylalanine.       Yes 
Yes 
-no 
after d-AMP 
No Yes No 
Genomics/ 
Metabolomics 
Enzymes 
metabolism 
Monoamine 
oxidase A 
(MAOA) 
Encodes a protein involved in the metabolism of DA, 5-HT, NE. 
Promoter 
VNTR 
no risk allele 
Other polymorphisms 
Yes    Yes Yes Yes    
Dopamine beta hydroxylase 
(DBH) 
Catalyzes the conversion of DA into NE. Expressed in the PFC. 
Intron V 
rs2519152 (TaqI) 
no risk allele 
5' Flank 
rs1611115 
(-1021 C/T) 
No risk allele 
Yes     Yes/No Yes    
Catechol-O-methyltransferase 
(COMT) 
Enzyme catalyzing the inactivation of DA within the PFC. Expressed in frontal lobe regions of 
brain. 
Exon IV 
rs4680 158Val/Met) 
no risk allele 
Yes    Yes      
Note: VNTR: variable number of tandem repeats; UTR: untranslated region; DA: dopamine; MRI: magnetic resonance imaging; MPH: methylphenidate; d-AMP: d-Amphetamine; MAOIs: Monoamine oxidase Inhibitors; Pycnogenol 
(PYC); Res: responders; BC: after Bonferroni correction 
Table 1. Data from genomic and metabolomic studies in dopaminergic, noradrenergic and biogenic trace amines
systems and metabolism enzymes classified according to neuropsychological, neuroimaging, treatment response,
biochemical and gene expression findings. Results from meta-analyses on the effects of treatments and peripheral
levels of the biomarkers.
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2.2.1.4. DA, Dihydroxyphenylacetic Acid (DOPAC) and Homovanillic Acid (HVA)
DA and its main metabolites DOPAC and HVA showed no difference in urine excretion in
ADHD patients compared with controls [12] (Table 1).
2.2.2. Noradrenergic neurotransmitter system
In 1971, Wender et al. [38] was the first to propose that symptoms usually present in ADHD,
such as hyperactivity, inattention and impulsivity, could be the result of abnormalities in the
dopaminergic and in noradrenergic neurotransmission system. The authors suggested that
noradrenergic system was disturbed in ADHD and that the stimulant medication used to treat
these symptoms acted on this neurotransmitter to compensate for the deficit. Indeed after
treatment with low dose of MPH, NE efflux increased within the pre-frontal cortex (PFC).
Moreover, the presumed method of action of atomoxetine is to increase extracellular levels of
NE in PFC.
2.2.2.1. Norepinephrine Transporter Gene (NET1, SLC6A2)
The SLC6A2 gene codes for the norepinephrine transporter, which is responsible for the re-
uptake of NE from the synaptic cleft back into the pre-synaptic neuron and is targeted by
atomoxetine. NET1 is most highly expressed in the frontal lobes where it plays a role in
noradrenergic and dopaminergic re-uptake. Although the meta-analysis of the most studied
polymorphism of rs5569 or G1287A (exon 9) showed negative results [11], an association was
observed in a genome-wide association study [39]. Moreover, allele G was linked to decreasing
in mean omission error scores after MPH administration [33] (Table 1).
Although few studies are available, other and different polymorphisms in this gene were
associated independently to some neuropsychological tasks and MPH or atomoxetine
response [33] (Table 1).
2.2.2.2. Norepinephrine (NE)
A recent meta-analysis [12] on peripheral urinary levels indicated higher concentrations in
ADHD compared with controls. (Table 1).
2.2.2.3. 3-Methoxy-4-Hydroxyphenylglycol (MHPG)
MHPG is the main metabolite of NE. According to a meta-analysis on its urinary levels [12],
the data showed a significant decrease in ADHD patients as compared to controls (Table 1).
2.2.2.4. Normetanephrine (NM) and Vanillylmandelic Acid (VMA)
Other metabolites studied are NM and VMA. According to a recent meta-analysis [12], the
urinary levels of NM showed no alterations in patients as compared to controls after Bonferroni
correction. Concerning VMA metabolite, contrasting results were reported on its urinary levels
[12] (Table 1).
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2.2.2.5. Neuropeptide Y (NPY)
NPY frequently co-localizes with catecholamine systems. It participates in the regulation of
feeding, circadian rhythms, reproduction, and thermoregulation. Some studies reported in
[12] confirmed increased plasma NPY concentrations in ADHD children compared with
controls and an association was observed between gene dose-dependent increases in NPY and
emotion processing (Table 1).
2.2.3. Biogenic trace amines
2.2.3.1. Phenylethylamine (PEA)
PEA is considered a trace amine because its urinary excretion rate and brain concentration are
very low compared to the other catecholamines. In dopaminergic neurons of the nigrostriatal
system, PEA is synthesized by the decarboxylation of phenylalanine and has the function to
stimulate the release of DA. According to some studies summarized in [12], urinary levels of
PEA are significantly lower in patients with ADHD compared with controls. Interestingly,
decreased levels of PEA have also been associated with symptoms of inattentiveness (Table 1).
2.2.4. Metabolism enzymes
Molecular studies have provided compelling evidence for the association of ADHD with genes
that encode enzymes involved in the metabolism of catecholamine and serotonin [8, 9].
2.2.4.1. Monoamine Oxidase A (MAOA)
The MAOA gene encodes a protein involved in the metabolism of DA, 5-HT and NE. Different
evidence link this gene to aetiopathogenetic mechanisms of ADHD including a MAOA
knockout mouse, showing an aggressive behaviour and higher monoaminergic neurotrans‐
mitter levels. Recent studies have focused mainly on a functional 30-bp VNTR 1.2 kb upstream
of the gene, but according to the meta-analysis [11], no association was found. This VNTR was,
however, linked to commission errors attenuated after MPH administration [33]. Other
polymorphisms, independently or in combination of haplotypes, were found associated to
specific neuropsychological tasks (i.e. motor control or visuo-spatial working memory, reward
deficiency or insufficient response inhibition) [33]. Concerning blood levels, the meta-analysis
[12] indicated reduced levels in ADHD compared with controls. MAO levels were associated
with increased inattention and impulsivity [12] (Table 1).
2.2.4.2. Dopamine Beta Hydroxylase (DBH)
The DBH gene encodes an enzyme that catalyzes the conversion of DA into NE which is
particularly expressed in the pre-frontal cortex. The polymorphism intron 5 TaqI (rs2519152)
was the most studied, whereas A–1021C/T variant (rs1611115), although a functional poly‐
morphism, was less investigated. A meta-analysisof these variants reported no association
with ADHD [11].
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However, A2/T allele was found associated with several neuropsychological tasks (poorer
performances on a temporal order judgment task, more commission and omission errors and
greater reaction time variability, more errors on measures of problem-solving and cognitive
impulsiveness). An association between neuropsychological measures of executive function
in children with ADHD and the –1021C/T variant has also been reported [33]. Concerning the
studies on its peripheral levels, patients with ADHD showed lower activities of DBH in serum
and urine, whereas no alterations were observed in plasma levels. It was suggested that
decreased DBH levels correlate with ADHD symptoms [12] (Table 1).
2.2.4.3. Catechol-O-Methyltransferase (COMT)
The COMT is an enzyme responsible for the degradation of DA and NE. It is highly expressed
in frontal lobe where it regulates synaptic DA levels. Most of the association studies between
COMT and ADHD susceptibility were focused on the well-known functional polymorphism
in exon 4 valine158 methionine (Val158Met). This SNP influences its enzyme activity because
homozygotes for the valine allele show greater activity than homozygotes for the methionine
allele. A recent meta-analysis [40] indicates no association between ADHD and the Val158Met.
However this polymorphism was found associated to (a) some neuropsychological tasks, (b)
antisocial and aggressive behaviours of ADHD, (c) response to MPH treatment [33] (Table 1).
3. Effects of ADHD treatments on peripheral levels of a biomarker in
dopaminergic and noradrenergic systems
Although several treatments for ADHD are available, there are no biological predictors of
treatment response that can be used in treatment planning. To address this gap in the literature,
we, for the first time, meta-analyzed studies assessing the effects of treatment on biomarkers
in dopaminergic, noradrenergic, biogenic trace amines systems and their principal metabo‐
lites. The effects of treatments on biomarkers may give insights into their mechanisms of action
and could be useful for developing hypotheses about biomarkers that might predict treatment
efficacy.
3.1. METHODS
3.1.1. Literature Search
To identify eligible studies for the meta-analysis, we searched two online electronic databases
(PubMed and Human Genome Epidemiology Network, HuGeNet), from inception until
December 2014, for all available studies on biomarkers and ADHD treatments in childhood.
The diagnostic search terms used to query the databases were “ADHD” and “Attention Deficit
Hyperactivity Disorder”. These two terms were used to conduct searches with all relevant
names of the biomarkers of interest along with different combinations of the following
keywords: dopamine, norepinephrine, metabolites, levels, peripheral, blood, urine, treatment,
clinical trial, methylphenidate, amphetamine, pemoline, pycnogenol, aspartame. Once articles
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had been collected, bibliographies were manually searched for additional eligible studies. The
literature search was performed by two individuals independently.
3.1.2. Inclusion and Exclusion Criteria
We included studies that (a) investigated one or more of the peripheral biomarkers described;
and (b) provided the features needed for performing meta-analyses. We excluded studies that:
(a) compared cases with ADHD with controls; (b) were case reports, (c) were commentaries
or reviews, (d) were not in English, (e) used adults or animal models, (f) selected samples based
on a disorder other than ADHD.
3.1.3. Data Extraction for Meta-analyses
For all studies suitable for meta-analyses, we extracted the following data from the original
publications: first author and year of publication, the number of participants, percent males,
mean age in years, study designs, biomarkers analyzed, drugs, dosage, treatment time
duration, results obtained (Table 2).
3.1.4. Statistical Analyses
Review Manager was used to analyze the data (RevMan Version 5.1.6; Copenhagen, The
Nordic Cochrane Centre, The Cochrane Collaboration, 2008). As reported in [12], we used the
fixed-effects model to generate a pooled effect size and 95% confidence interval (CI) from
individual study effect sizes (the standardized mean difference [SMD]) using the inverse
variance method. The significance of the pooled effect sizes was determined by the z-test.
Between study, heterogeneity was assessed using a χ2 test of goodness of fit test and the I2
statistic. We used a p value of 0.05 to assert statistical significance. In instances where the results
showed a significant effect in the presence of significant between-study heterogeneity, a
random effects model was used, with effect sizes pooled using the DerSimonian and Laird
method.
Publication bias was estimated by the method of Egger et al. [41] which uses a linear regression
approach to measure funnel plot asymmetry on the natural logarithm scale of the OR. The
significance of the intercept (a) was determined by the t test [41]. The rank correlation method
and regression method tests were conducted by MIX version 1.7. (http://www.mix-for-meta-
analysis.info).
Because we conducted 8 meta-analyses to assess the significance of biomarkers, our Bonferroni
corrected significance level was 0.006.
3.1.5. Behavioural methods
The main scales to address behavioural modifications/response to drugs were Conners
Teacher/Parent Rating Scales [42–54, 23]. Moreover, other tests/scales were used: Physical and
Neurological Examination for Soft Signs [47, 53, 46, 55], Multigrade Inventory for Teachers,
Matching Familiar Figures Test, Children’s Checking Task, Wisconsin Card Sorting Test,
Airplane Test [42], Children’s Global Assessment and Impression Scales, Child (Attention
Problems) Teacher Rating scale, Wechsler Intelligence Scale for Children [47, 54, 23].
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First author, Published
year 
Patients sample 
size 
%Males Age * Study  design Biomarkers Treatments Dosage 
Treatment time 
duration 
Results 
Wender et al. [38] 9 89 9 y P vs. T HVA, NE, NM, VMA, MHPG d-AMP 10–20 mg/day 1 week d-AMP increased NM 
Shekim et al. [55] 6 100 9 y P vs. T MHPG, NM, HVA d-AMP 0.5 mg/kg/day 2 weeks d-AMP depressed MHPG, NM 
Rapoport et al. [46] 13 100 9 y P vs. T MHPG, HVA, NE, DA d-AMP 0.5 mg/kg/day nr 
d-AMP decreased MHPG, 
HVA 
Shekim et al. [56] 10 100 9 y B vs. T MHPG d-AMP 0.5 mg/kg/day 2 weeks d-AMP decreased MHPG 
Shekim et al. [51] 21 100 9 y B vs. T MHPG, NM d-AMP 0.5 mg/kg/day 2 weeks d-AMP decreased MHPG (R) 
Shekim et al. [53] 15 100 9 y B vs. T MHPG d-AMP 0.5 mg/kg/day 2 weeks d-AMP decreased MHPG (R) 
Brown et al. [50] 8 100 7 y P vs. T MHPG, HVA d-AMP 0.74±0.98 mg/kg/day 1 week d-AMP decreased MHPG 
Shekim et al. [54] 21 100 9 y R vs. NR MHPG, HVA d-AMP 0.5 mg/kg/day 2 weeks d-AMP decreased MHPG (R) 
Shekim et al. [49] 9 100 13 y B vs. T MHPG, HVA d-AMP 0.5 mg/kg/day 2 weeks 
d-AMP decreased MHPG, 
increased HVA 
Shen and Wang [52] 38 95 9 y B vs. T MHPG MPH 0.3 mg/kg/day 3 weeks MPH decreased MHPG 
Zametkin et al. [58] 12 100 9 y P vs. T PEA d-AMP 0.75 mg/kg/day 2 weeks d-AMP increased PEA 
Zametkin et al. [44] 10 100 9 y B vs. T 
NE, VMA, NM, MHPG, DA, DOPAC,
HVA, PEA 
MPH, d-AMP 
0.85±0.12 mg/kg/day 0.69 
mg/kg 
2 weeks 
d-AMP decreased DA, 
DOPAC,HVA, NE, 
MHPG,VMA 
Zametkin et al. [45] 5 100 9 y B vs. T 
MHPG, NE, NM, VMA, DA, HVA, 
DOPAC, PEA 
d-AMP, MAOIs 
13.21±2.5 mg 
12.13±4.5 mg clorgyline, 
10.40±1.1 mg 
tranylcypromine sulfate 
4 weeks 
d-AMP decreased MHPG, NE, 
NM, VMA 
MAOIs decreased MHPG, 
VMA, HVA, DOPAC; 
increased NM 
Zametkin et al. [43] 11 100 8 y B vs. T 
NE, NM, MHPG, VMA, DA, HVA, 
PEA 
Pemoline 2.9±0.31 mg/kg/day 4 weeks No alterations 
Zametkin et al. [48] 11 100 9 y B vs. T 
NE, NM, MHPG, VMA, HVA, 
DOPAC 
MPH 0.74±0.21 mg/kg 2 weeks MPH decreased NM 
Elia et al. [47] 24 100 8 y P vs. T 
NE, MHPG, VMA, HVA, NM, 
DOPAC 
d-AMP, MPH 
up to 1.5 mg/kg/day 
up to 3 mg/kg/day 
3 weeks 
d-AMP decreased MHPG, 
VMA 
Shaywitz et al. [42] 15 73 9 y P vs. T NE, DA, HVA Aspartame 34 mg/kg 2 weeks No alterations 
Kusaga et al. [57] 22 nr:nr 9 y R vs. NR MHPG, PEA, HVA MPH 0.3 to 0.5 mg/kg/day Nr No alterations (R, NR) 
Dvokovka et al. [23] 40 82 10 y P vs. T NE, DA Pycnogenol 1 mg/kg/day 4 weeks Pyc decreased NE 
Note: * age is represented in mean/years; y = years; nr = not reported; DA = dopamine; HVA = homovanillic acid; DOPAC = 3,4-dihydroxyphenylacetic acid; NE = norepinephrine; MHPG = 3-methoxy-4-
hydroxyphenylethylene glycol; NM = normetanephrine; VMA = vanillylmandelic acid; MPH = methylphenidate; d-AMP = dextro-amphetamine; MAOIs = monoamine oxidase inhibitors; P = placebo; T = treatment; B = 
baseline; R = responders; NR = no responders 
Table 2. Summary of studies on the ADHD treatments and peripheral levels of biomarkers in dopaminergic,
noradrenergic and biogenic trace amines systems included in the meta-analyses.
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3.2. Results
After screening of papers according to the inclusion/exclusion criteria, 35 ADHD treatments
studies that focused on alterations in the principal metabolites and metabolism enzymes of
dopaminergic and noradrenergic neurotransmission pathways were reported.
The main studies suitable for performing meta-analyses on ADHD treatments and peripheral
biomarkers in dopaminergic, noradrenergic and biogenic trace amines systems are described
in Table 2.
All the analyses presented below use the SMD as the effect size.
Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 1. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary dopamine (DA) lev‐
els.
3.2.1. Dopamine neurotransmitter system
3.2.1.1. DA and DOPAC
Urinary levels of DA [23, 42-46] and its metabolite DOPAC [47, 48, 44, 45] were investigated
in several studies included in the meta-analyses. The results indicated no alteration in DA
levels after d-AMP treatment (Z = 1.62 p = 0.11), with a slight heterogeneity in effect sizes among
the studies (p = 0.04, I2=69%). Other treatments (MPH, aspartame, pemoline, MAOIs, pycno‐
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genol) did not influence its levels (Figure 1). No clinically significant effect on the behaviour
and cognitive status of children with ADHD was observed after aspartame, pemoline,
pcynogenol and MAOIs [42, 45, 43, 23], as well as in relation to d-AMP treatments.
Similarly, urinary DOPAC levels were similar between treated and not-treated patients with
ADHD both after MPH (Z = 0.08, p = 0.93) and after d-AMP (Z = 1.10, p = 0.27) treatment.
Significant heterogeneity in effect sizes across studies was observed for d-AMP (p = 0.0001, I2
= 89%). The difference observed after MAOIs treatment (Z = 2.38, p = 0.02) was lost after
Bonferroni correction (Figure 2) and no clinical effect in children with ADHD was observed
[45]. Similarity, there were no correlations between DOPAC levels and behavioural improve‐
ments after MPH and d-AMP treatments.
Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 2. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary metabolite dihydrox‐
yphenylacetic acid (DOPAC) levels.
3.2.1.2. Homovanilic Acid (HVA)
Eleven studies assessed the DA metabolite HVA in urine [42, 47, 48, 43-45, 49, 50, 46, 55, 38].
No alterations in HVA levels were observed after MPH (Z = 0.09, p = 0.93) and after d-AMP
(Z = 1.76, p = 0.08) treatment. Significant heterogeneity in effect sizes across studies was
observed after d-AMP treatment (p = 0.0001, I2 = 76%). Only one study [45] reported reduced
HVA levels after MAOIs treatment (Z = 3.46, p = 0005), but no correlation with behavioural
features was observed (Figure 3). No clinical effect on the behaviour and cognitive status of
children with ADHD was observed after aspartame, pemoline and MAOIs [42, 45, 43], as well
as after MPH and d-AMP treatments.
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Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 3. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary homovanilic acid
(HVA) levels.
3.2.2. Noradrenergic neurotransmitter system
3.2.2.1. NE
Our meta-analyses for NE included nine studies [23, 42, 47, 48, 43–46, 38] and showed no
difference in urinary levels in treated patients with ADHD compared with those not treated
(MPH: Z = 0.81, p = 0.42; d-AMP Z = 1.55, p = 0.12), with heterogeneity in effect sizes across
studies for d-AMP (p = 0.0002, I2 = 82%) (Figure 4). Significant reduction of urinary NE was
observed after pycnogenol treatment (Z = 3.08, p = 0.002) (Figure 4), with consequently less
hyperactivity [23] (Table 1). No clinical effect on the behaviour and cognitive status of children
with ADHD was observed after aspartame, pemoline and MAOIs [42, 45, 43] and similarly
with MPH and d-AMP treatments.
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Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 4. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary norepinephrine (NE)
levels.
3.2.2.2. Methoxy-4-hydroxyphenylglycol (MHPG)
Another widely studied metabolite of NE is MHPG. Fourteen studies provided data for our
meta-analysis [47, 48, 43-45, 52, 49, 50, 56, 51, 53, 46, 55, 38]. We found significantly lower
urinary MHPG levels in treated compared with not-treated patients after d-AMP treatment
(d = 0.89, Z = 6.23, p < 0.00001), significant after Bonferroni correction. No heterogeneity of effect
sizes across studies was observed. Concerning the results about MPH, a trend of significance
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was reported (Z = 1.85, p = 0.06), but it was lost after Bonferroni correction. Only one study
reported a significant decrease after MAOIs treatment (Z = 4.21, p < 0.0001) [45] (Figure 5).
Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 5. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary 3-methoxy-4-hydrox‐
yphenylethylene glycol (MHPG) levels.
Moreover, with the aim to assess whether MHPG can be a potential predictor of the treatment
response, we have meta-analyzed studies that reported MHPG urinary levels among res‐
ponders and no responders pre- and post-treatment [57, 54, 53, 51]. The results indicated that
MHPG urinary levels are reduced by stimulants in the responders (Z = 2.66, p = 0.008) but not
in the no-responders (Z = 0.16, p = 0.87) (Figure 6).
Significant correlations were observed between lower levels of MHPG and behavioural
improvements after d-AMP administration [45, 49, 54, 50, 51, 53] (Table 1), whereas no
significant correlation was observed after MPH [48], or MAOIs [45] or pemoline [43] treat‐
ments.
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Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis.
Figure 6. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary 3-methoxy-4-hydrox‐
yphenylethylene glycol (MHPG) levels in responders and no responders and pre-post d-AMP treatment.
Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 7. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary normetanephrine
(NM) levels.
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Following the Egger et al. [41] method, we have tested the presence of publication bias (is a
bias with regard to what is likely to be published, among what is available to be published)
for all biomarkers analyzed. Only in the case of MHPG, we observed a slight significant
presence of publication bias (p = 0.05, data not shown). However when the study from
Zametkin et al. [45] was excluded, this difference disappears (p = 0.21, data not shown).
3.2.2.3. Normetanephrine (NM)
The main metabolite of NE is NM. The meta-analysis of NM included eight studies [47, 48, 43–
45, 51, 55, 38]. No differences in urinary NM levels were observed between treated and not-
treated patients after MPH (Z = 0.42, p = 0.68) and after d-AMP (Z = 1.25, p = 0.21) treatments,
with heterogeneity of effect sizes across studies for MPH (p < 0.00001, I2 = 92%). One study
reported no alteration after pemoline treatment, with no correlation with behavioural im‐
provements [43] and one study indicated increased levels of NM after MAOIs treatment with
no evidence of correlation with behavioural features (Z = 3.23, p = 0.001) [45] (Figure 7).
3.2.2.4. Vanillylmandelic Acid (VMA)
Other metabolites studied are VMA. Six studies were available for meta-analyses [47, 48, 43–
45, 38] and the results indicated significant difference after d-AMP treatment (Z = 2.12, p = 0.03)
but lost after Bonferroni correction. Significant difference was observed for the presence of
heterogeneity in effect size across the studies (p < 0.0001, I2 = 86%). Reduced levels of VMA
after MAOIs treatment were observed in only one study [45] (Z = 4.45, p < 0.00001), in absence
of significant correlation with behavioural improvements. Moreover, no alteration was
observed after pemoline treatment along with no clinically significant effect on the behaviour
of children with ADHD [43] (Figure 8).
3.2.3. Biogenic trace amines
3.2.3.1. PEA
Although there are not enough studies for performing meta-analysis, administration of d-AMP
resulted in an increased urinary excretion of PEA [44, 58, 57]. However, no correlation was
observed between PEA levels and the ADHD severity [57, 58] (Table 1). No alterations were
observed after MPH, MAOIs, and pemoline treatments [43–45].
4. Discussion and future research
This chapter has two main aims: (a) to define a hypothetical signature of a set of genetic and
biochemical markers useful for the ADHD diagnosis; (b) to determine whether the treatment
changes the levels of a biomarker to be useful, if tested, as a predictor of treatment response.
In Table 1, we summarized the results obtained from this work, providing an overview of the
significant findings that emerged by the different analyses.
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Starting from the literature, we support evidence that SLC6A3 and DRD4 represent the best
potential genetic markers for ADHD diagnosis. As reported in [33], allele 10R in SLC6A3 gene,
susceptibility risk allele and associated to higher DA concentrations and higher DAT1 density
in basal ganglia, is linked to different and specific neuropsychological tasks, generates more
activation in specific brain areas, reduced brain structure and is associated to drugs response.
Interestingly a reverse association has been seen for ADHD adults where it is the 9R instead
of 10R, the risk allele [59]. This suggests that this allele can be a good candidate also for
discriminating ADHD in children vs. ADHD in adults.
Similarly 7R in DRD4 gene, susceptibility risk allele and linked to less responsivity to DA, is
involved in some cognitive features, brain structure and functioning, drugs response and
expression levels of DRD4.
In the second line, we co-localize the metabolite MHPG, the enzyme MAOA, NE and SLC6A2
as good candidates as markers for ADHD. They were found associated to peripheral levels
altered in ADHD, to some neuropsychological tasks, treatment response and symptomatology.
In the third line, interesting results come from DBH and COMT enzymes. Although the meta-
analyses of Taq1 and –1021 T/C in DBH gene and 158Val/Met in COMT gene have not identified
susceptibility alleles, variants of these genes are associated with neuropsychological perform‐
ance, peripheral levels, treatment response and symptomatology.
Captions: Chi2 = χ2 test of goodness of fit; Tau2 = estimate of the between-study variance in a random-effects meta-
analysis; methylphenidate (MPH); dextroamphetamine (d-AMP); monoamine oxidase inhibitors (MAOIs).
Figure 8. Random forest plot for standard mean differences (SMD) from meta-analysis of urinary vanillylmandelic
acid (VMA) levels.
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Although the studies are often opposite or contradictory due to the heterogeneity of the
disorder, SLC6A3, DRD4, MHPG, MAOA, NE, SLC6A2, DBH, COMT could represent, in this
order, a hypothetical signature of a set of genetic and biochemical markers useful for ADHD
diagnosis. In the absence of medications, peripheral levels of MAOA, DBH and also PEA were
observed correlated with ADHD behaviour. Of this hypothetical signature, SLC6A3 10R,
DRD4 7R, COMT val158met, MAOA were also associated to major depressive disorder (MDD),
schizophrenia, schizophrenia/anxiety disorders/bipolar disorder and obsessive-compulsive
disorder, respectively [60]. Moreover, peripheral levels of MHPG have been found associated
to manic syndrome in bipolar disorder [61], to microstructural changes within the cerebellum
in first-episode schizophrenia [62] and to melancholic MDD, even though without correlation
with duration/severity of depressive symptoms [63]. However, these findings, if they are
lacking specificity, on the other hand, suggest the common biological mechanisms linked to
dopaminergic and noradrenergic systems shareable with different psychiatric disorders, as
recently supported [60].
In relation to the meta-analyses on the peripheral alterations of a biomarker after treatment,
the results located, for the first time, the NE metabolite MHPG as the main molecule whose
urinary levels are influenced by the d-AMP treatment. This association was significant also
after Bonferroni correction. The other molecules such as DA, DOPAC, HVA, NE, NM, VMA
are not modified by the stimulants treatment and they are not correlated with behavioural
modifications after different drugs. Although there are not enough studies, suggestive results
have been obtained for PEA molecule, even though no evidence of correlation between
peripheral levels and behavioural features was observed after d-AMP treatment (see Table 1).
Moreover, we found a slight evidence of publication bias for MHPG and a significant hetero‐
geneity of effect sizes across studies for all biomarkers that significantly differentiated treated
ADHD patients from untreated.
Considering the present data along with the recent meta-analysis [12], MHPG could be a
potential biomarker for ADHD diagnosis and a potential predictor of treatment response.
Indeed, when we compared urinary levels of MHPG among patients with ADHD and control
subjects, the meta-analysis [12] indicated a significant decrease in patients. Similarly, the
administration of d-AMP significantly reduced the urinary levels of MHPG (present data).
This, along with the well-reported correlation between decrease in MHPG and behavioural
improvements after d-AMP treatment [45, 49, 54, 50, 51, 53] (see Table 1), focuses attention on
MHPG as a potential mediator of stimulant drug response, in addition to a useful biological
marker for diagnostic assessment. More interestingly, urinary MHPG levels are decreased after
stimulants administration only in the responders patients, indicating that MHPG could be a
useful predictor of the stimulants response.
The metabolite MHPG is a major product of NE breakdown. A significant fraction of urinary
MHPG (as much as 30–50%) comes from the metabolism of NE in the CNS in man. This is
supported by some evidence that destruction of NE terminals in the CNS of animals resulted
in decreased urinary levels of MHPG. Moreover, MHPG excretion in urine has been shown to
vary in response to changes in sympathetic activity or stressful situations. According to some
authors [51], reduced MHPG may be considered linked to decreased activity of MAO enzyme.
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Indeed, the results of the meta-analysis [12] demonstrated lower MAO and MHPG and higher
NE concentrations in patients with ADHD, supporting the current hypothesis that reduced
MAO activity impairs the degradation of NE and leads to lower levels of MHPG in patients
with ADHD.
Our results on the treatment contribute also to clarify the mechanism of action of d-AMP on
the MHPG levels. In agreement with some authors [51], we hypothesized that d-AMP, by
inhibiting the re-uptake of NE by the pre-synaptic nerve terminal and the intraneuronal MAO,
tends to decrease MHPG. A similar mechanism could be hypothesized also for MPH because,
although the results are negative (p = 0.06 see Figure 5), three studies [52, 48, 44] confirmed
lower levels of MHPG in treated patients with ADHD. This supports also the evidence that d-
AMP and MPH are remarkably similar in their clinical effects.
Few studies have been conducted on other medications such as pycnogenol, pemoline and
MAOIs, which make it difficult to interpret the lack of statistical significance for these medi‐
cations. To date, the current evidence is insufficient to support the use of pycnogenol for the
treatment of any chronic disorder including ADHD and well-designed, adequately powered
trials are needed to establish the value of this treatment [64]. Concerning pemoline, because
15 cases of acute fulminant hepatic failure with this treatment have been reported, its use has
been relegated to only rare circumstances [65, 66]. Moreover, MAOIs are a group of antide‐
pressants that can treat ADHD with some benefit, but are rarely used because they have
significant and sometimes dangerous side effects and can dangerously interact with foods and
other medications. Finally, one study [42] reported the biochemical monoamine determina‐
tions in relation to aspartame treatment. They demonstrated that aspartame at greater than 10
times usual consumption has no effect on the cognitive and behavioural status of children with
ADHD. In addition, aspartame does not appear to affect the urinary excretion rates of
monoamines and metabolites [42].
These data in general suffer of one important limitation that is specificity/sensitivity. All papers
reported in the review and in the different meta-analyses are lacking this information. It is also
important to highlight that most of these studies were conducted around ‘80s, ‘90s. Moreover,
the data related to meta-analyses analyzing the effects of the treatment on a biomarker have
some further limitations. In particular, (a) we found significant heterogeneity in effect size
across the studies for all biomarkers analyzed. This could be due to several issues: (1) no
homogeneity in the study designs because some studies used a placebo or baseline approach;
(2) different concentrations of drugs used in the several studies; (3) different treatment time
duration (from 1 week to 15 weeks); (4) methods to value the treatment response; (5) meth‐
odological procedures: repeated measurements on each child were not performed in all
studies; over time, several methods for measuring catecholamines were used [67] (studies
include a wide temporal range: urine levels of DA: from 1978 to 2007; HVA: from 1971 to 1994;
NE: from 1971 to 2007; VMA: from 1971 to 1988); (6) many of the studies were generated by
the same group (Shekim and Zametkin); (7) low significant effect sizes [68]. (b) The presence
of publication bias for MHPG. This was due by the paper from Zametkin et al. [45]. However,
when this paper was eliminated, the Egger test was not significant (p = 0.21 data not shown)
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and the meta-analysis for this metabolite was still significant (d = 0.62, Z = 6.27, p < 0.00001 with
less heterogeneity p = 0.09, I2 = 34%, data not shown).
Future research should be focused on the replication of these findings, to assess their specificity
for ADHD, and to quantify the degree to which they are sufficiently precise to be useful in
clinical settings. Thus more work is needed to determine whether the statistical significance
of our findings translate into diagnostic utility. Moreover, future studies will have to take into
account the deep integration of "omics" sciences such as the “pharmacogenomics”, "phenom‐
ics", "epigenomic", "proteomics", “transcriptomic”, "metabolomics". To date, the use of high–
throughput computational methods such as learning machinery permits to integrate the
complex network of genes (DNA, RNA), proteins and biochemical interactions along with
clinical and endophenotype profiling including therapeutic response to identify a set of
biomarkers useful for the diagnostic assessment and for the personalization of therapies.
5. Conclusion
Currently, no biomarkers for ADHD have achieved the status of clinical utility as a diagnostic
tool. This chapter supports evidence for a role of some dopaminergic and noradrenergic
molecules, their metabolites and metabolism enzymes such as SLC6A3, DRD4, MHPG, MAOA,
NE, SLC6A2, DBH, COMT that could represent, in this order, a hypothetical signature of a set
of genetic and biochemical markers useful for ADHD diagnosis. Moreover, this chapter
demonstrates, for the first time, with a meta-analytic method, that d-AMP influences urinary
MHPG levels and that, if it is tested, MHPG could be a useful predictor of response to
stimulants. Although further studies are needed mainly in relation to specificity and sensitiv‐
ity, we speculate that MHPG could be the best potential candidate as biomarker for ADHD.
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